Is Puma Biotechnology, Inc. overvalued or undervalued?

As of 10 June 2025, Puma Biotechnology, Inc. has moved from an attractive to a very attractive valuation grade. The company is currently undervalued, with a P/E ratio of 5, a price-to-book value of 1.90, and an EV to EBITDA ratio of 3.15. Notably, Puma's PEG ratio stands at an impressive 0.04, indicating strong growth potential relative to its valuation.
In comparison to its peers, Puma Biotechnology demonstrates a more favorable valuation, with Zevra Therapeutics, Inc. showing a negative P/E of -5.05 and an EV to EBITDA of -7.34, while Alimera Sciences, Inc. has a P/E of -23.11 and an EV to EBITDA of 27.26. Despite recent underperformance in the short term, with a 1-week return of -2.90% compared to the S&P 500's -0.13%, Puma's year-to-date return of 9.84% outpaces the S&P 500's 2.44%, reinforcing its undervalued status in the market.